Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03676868
Recruiting Observational

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

NCT03676868 · tracked via the Priya Life Science France tracker
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Observational
Started
2018-11-20
Last updated
2025-06-25

Condition(s) studied

Cerebral Arteriovenous MalformationsRuptured or Unruptured Cerebral Arteriovenous Malformations

Study summary

The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation.

The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke.

The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

Eligibility

Sex
ALL
Min age
0 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient over 18 years old * Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring * Express consent to participate in the study And * children * Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority Exclusion Criteria: * Patient benefiting from a legal protection measure * Pregnant or breast feeding woman

Primary outcome measure(s)

  • Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic — 6 months
    associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome
  • Associaton between dosage of platelet and the arteriovenous malformation pronostic — 6 months
    Dosage of platelet in blood samples and correlation with clinical outcome
  • Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic — 6 months
    Dosage of neutrophilic in blood samples and correlation with clinical outcome
  • Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic — 6 months
    Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome

Trial sites (1)

FacilityCityRegionStatus
Fondation Ophtalmologique Rotschild Paris France Recruiting

More Fondation Ophtalmologique Adolphe de Rothschild trials in France

Cardiac Involvement in Wilson's Disease Recruiting
Identifying New Genetic Causes to Development Disorders Recruiting
Optimization of Sequences to Improve the Quality and Comfort of the Magnetic Resonance Imaging Examination Recruiting
Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype Correlation Recruiting
RESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy Recruiting

Other trials for the same condition

Liquid Biopsies for Detecting Somatic Mutations in Sporadic Cerebral Arteriovenous Malformations. Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03676868 on ClinicalTrials.gov ↗ ← All trials in France